PELONews: New partner KELI Therapeutics for human placenta derived MSCs and EVs

We are beyond excited to announce our new partnership with KELI Therapeutics!

KELI Therapeutics provides products not only for preclinical research but also soon clinical studies as everything is produced in GMP-like conditions and the GMP license is on the way. They specialize in human placenta derived MSCs and the EVs they produce, while also providing specialized media without exosomes! Did you know that the placenta has contributions from both maternal and fetal tissue which in turn increases diversity within the cells and makes for a very interesting culture. Want to know more? Contact us!

#supplierspotlight #3dcellculture #animalfreeresearch #3rs #stemcells #MSCs #EVs #exosomes #GMP #regenerativemedicine #innovation #cells